Patents by Inventor Grayson Lipford
Grayson Lipford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8283328Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: GrantFiled: August 19, 2003Date of Patent: October 9, 2012Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Grayson Lipford, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Patent number: 8153141Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: GrantFiled: April 4, 2003Date of Patent: April 10, 2012Assignee: Coley Pharmaceutical GmbHInventors: Grayson Lipford, Stefan Bauer, Hermann Wagner
-
Publication number: 20090060927Abstract: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.Type: ApplicationFiled: March 26, 2004Publication date: March 5, 2009Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford, Klaus Heeg
-
Publication number: 20070232622Abstract: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.Type: ApplicationFiled: October 4, 2006Publication date: October 4, 2007Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Grayson Lipford, Alexandra Forsbach, Charles Zepp
-
Publication number: 20070224210Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: ApplicationFiled: October 4, 2006Publication date: September 27, 2007Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Grayson Lipford, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Publication number: 20070184465Abstract: The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.Type: ApplicationFiled: November 10, 2006Publication date: August 9, 2007Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford
-
Publication number: 20070142315Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: November 22, 2006Publication date: June 21, 2007Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jorg Vollmer, Grayson Lipford
-
Publication number: 20060241076Abstract: The invention provides immunostimulatory compositions and methods for their use. In particular, the immunostimulatory compositions of the invention include RNA-like polymers that incorporate an immunostimulatory sequence motif and at least one chemical modification to confer improved stability against nuclease degradation and improved activity. Specific modifications involving phosphate linkages, nucleotide analogs, and combinations thereof are provided. Compositions of the invention optionally include an antigen and can be used to stimulate an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, or asthma. Modified oligoribonucleotide analogs of the invention are believed to stimulate Toll-like receptors TLR7 and TLR8.Type: ApplicationFiled: April 26, 2006Publication date: October 26, 2006Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Eugen Uhlmann, Arthur Krieg, Grayson Lipford
-
Publication number: 20060172966Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: ApplicationFiled: March 3, 2006Publication date: August 3, 2006Applicant: Coley Pharmaceutical GmbHInventors: Grayson Lipford, Stefan Bauer, Hermann Wagner
-
Patent number: 7001890Abstract: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.Type: GrantFiled: January 23, 1998Date of Patent: February 21, 2006Assignee: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford, Klaus Heeg
-
Publication number: 20050256073Abstract: Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3? terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5?-C/U-U-G/U-U-3?. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new and existing oligonucleotides, including CpG oligodeoxynucleotides. Also provided are methods for use of the immunostimulatory RNA oligonucleotides and DNA:RNA chimeric oligonucleotides of the invention to induce an immune response in vitro and in vivo, as well as to treat allergy, asthma, infection, and cancer in a subject. Single-stranded oligoribonucleotides of the invention are believed to signal through a Toll-like receptor (TLR) chosen from TLR9, TLR8, TLR7, and TLR3. The oligoribonucleotides can also be used in a method to screen for TLR antagonists.Type: ApplicationFiled: February 18, 2005Publication date: November 17, 2005Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Grayson Lipford, Alexandra Forsbach
-
Publication number: 20050215501Abstract: The invention relates to methods for inducing epitope specific immune responses by combining an immunostimulant therapy with a therapeutic protocol.Type: ApplicationFiled: October 25, 2004Publication date: September 29, 2005Applicant: Coley Pharmaceutical Group, Inc.Inventors: Grayson Lipford, John Whisnant
-
Patent number: 6943240Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.Type: GrantFiled: September 17, 2001Date of Patent: September 13, 2005Assignee: Coley Pharmaceuticals GmbHInventors: Stefan Bauer, Grayson Lipford, Hermann Wagner
-
Publication number: 20050181422Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.Type: ApplicationFiled: March 18, 2005Publication date: August 18, 2005Applicant: Coley Pharmaceutical GmbHInventors: Stefan Bauer, Grayson Lipford, Hermann Wagner
-
Publication number: 20050119273Abstract: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.Type: ApplicationFiled: June 18, 2004Publication date: June 2, 2005Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Grayson Lipford, Alexandra Forsbach, Charles Zepp
-
Publication number: 20050100983Abstract: The invention is directed to methods for screening for a compound that affects interaction between a Toll-like receptor (TLR) and a ligand for the TLR. The methods involve direct measurement of interaction using, for example, surface plasmon resonance (SPR), particularly under conditions of pH that mimic those of the TLR in vivo. Compounds identified using the methods of the invention may be useful in the development of agents useful in the treatment of conditions characterized by undesirable immune activation, e.g., autoimmunity, inflammation, allergy, asthma, and transplantation.Type: ApplicationFiled: November 5, 2004Publication date: May 12, 2005Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc., Technische Universitat MunchenInventors: Stefan Bauer, Grayson Lipford, Hermann Wagner, Mark Rutz
-
Publication number: 20050059619Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: ApplicationFiled: August 19, 2003Publication date: March 17, 2005Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Grayson Lipford, Robert Rankin
-
Publication number: 20050054601Abstract: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.Type: ApplicationFiled: July 16, 2004Publication date: March 10, 2005Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford, Klaus Heeg
-
Publication number: 20040234512Abstract: The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.Type: ApplicationFiled: June 25, 2004Publication date: November 25, 2004Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford
-
Publication number: 20040030118Abstract: The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.Type: ApplicationFiled: February 24, 2003Publication date: February 12, 2004Inventors: Hermann Wagner, Grayson Lipford